Economic burden of treatment for diffuse large b-cell lymphoma

A research team has confirmed expectations of higher healthcare utilization and costs with relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Source: ScienceDaily Headlines - December 5, 2016 Category: Science Source Type: news